日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Effects of age and gender on immunogenicity and reactogenicity of SpikoGen recombinant spike protein vaccine: a post-hoc analysis

年龄和性别对SpikoGen重组刺突蛋白疫苗免疫原性和反应原性的影响：一项事后分析

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-024-67945-3
Anjidani, Nassim; Shahpari, Ramin; Kafi, Hamidreza; Petrovsky, Nikolai; Barati, Saghar
免疫/内分泌
发表日期：2024
文献求助 收藏

Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial

评估 SpikoGen®（一种含 Advax-CpG55.2 佐剂的严重急性呼吸综合征冠状病毒 2 刺突蛋白疫苗）的有效性和安全性：一项 3 期随机安慰剂对照试验

期刊:Clinical Microbiology and Infection
影响因子:8.5
doi:10.1016/j.cmi.2022.09.001
Tabarsi, Payam; Anjidani, Nassim; Shahpari, Ramin; Mardani, Masoud; Sabzvari, Araz; Yazdani, Babak; Kafi, Hamidreza; Fallah, Newsha; Ebrahimi, Ali; Taheri, Ali; Petrovsky, Nikolai; Barati, Saghar
微生物学
发表日期：2023
文献求助 收藏

Safety and Effectiveness of Cinnomer(®) on Disease Characteristics, Depression, and Quality of Life of Patients with Multiple Sclerosis: A Phase IV, Post-marketing, Prospective, Multicenter Study

辛诺默®对多发性硬化症患者疾病特征、抑郁症和生活质量的安全性和有效性：一项IV期上市后前瞻性多中心研究

期刊:Archives of Iranian Medicine
影响因子:1
doi:10.34172/aim.2023.95
Naser Moghadasi, Abdorreza; Ashtari, Fereshteh; Baghbanian, Seyed Mohammad; Shaygannejad, Vahid; Anjidani, Nassim; Ghadiri, Fereshteh; Sedighi, Behnaz; Saeidi, Morteza; Amirifard, Hamed; Ayromlou, Hormoz; Beladi Moghadam, Nahid; Ranjbar, Mohammad Bagher; Nazeri, Masoume; Niknam, Zahra; Faraji, Fardin; Afsorde, Afsaneh; Sahraian, Mohammad Ali
神经科学
抑郁症
多发性硬化症
发表日期：2023
文献求助 收藏

Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations

SpikoGen®（一种添加Advax-CpG55.2佐剂的SARS-CoV-2刺突蛋白疫苗）的安全性和免疫原性：一项在血清阳性和血清阴性人群中进行的2期随机安慰剂对照试验

期刊:Clinical Microbiology and Infection
影响因子:8.5
doi:10.1016/j.cmi.2022.04.004
Tabarsi, Payam; Anjidani, Nassim; Shahpari, Ramin; Mardani, Masoud; Sabzvari, Araz; Yazdani, Babak; Roshanzamir, Khashayar; Bayatani, Behnam; Taheri, Ali; Petrovsky, Nikolai; Li, Lei; Barati, Saghar
SARS-CoV-2
免疫/内分泌
发表日期：2022
文献求助 收藏

Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

生物类似药地诺单抗候选药物（Arylia）与参考产品（Prolia®）在绝经后骨质疏松症中的疗效和安全性比较：一项III期、随机、双臂、双盲、平行、阳性对照、非劣效性临床试验

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-022-02840-8
Jamshidi, Ahmadreza; Vojdanian, Mahdi; Soroush, Mohsen; Akbarian, Mahmoud; Aghaei, Mehrdad; Hajiabbasi, Asghar; Mirfeizi, Zahra; Khabbazi, Alireza; Alishiri, Gholamhosein; Haghighi, Anousheh; Salimzadeh, Ahmad; Karimzadeh, Hadi; Shirani, Fatemeh; Fard, Mohammad Reza Hatef; Nazarinia, MohammadAli; Soroosh, Soosan; Anjidani, Nassim; Gharibdoost, Farhad
代谢
骨质疏松
发表日期：2022
文献求助 收藏

Immunogenicity and Safety of SpikoGen, an Adjuvanted Recombinant SARS-CoV-2 Spike Protein, as a Heterologous Third Booster Dose in Kidney Transplant Patients: A Single-arm Clinical Trial

SpikoGen（一种佐剂重组SARS-CoV-2刺突蛋白）作为异源第三次加强剂量在肾移植患者中的免疫原性和安全性：一项单臂临床试验

期刊:Clinical Therapeutics
影响因子:3.6
doi:10.1016/j.clinthera.2022.10.002
Nafar, Mohsen; Mostafaloo, Narges; Firouzan, Ahmad; Poorrezagholi, Fatemeh; Samadian, Fariba; Dalili, Nooshin; Barati, Saghar; Anjidani, Nassim; Kafi, Hamidreza; Shahpari, Ramin; Bayat, Mahdiye; Kianipour, Soha; Samavat, Shiva
SARS-CoV-2
免疫/内分泌
发表日期：2022
文献求助 收藏

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

比较拟上市的帕妥珠单抗生物类似药P013与参考产品在HER2阳性乳腺癌患者中的疗效和安全性：一项随机、III期等效性临床试验

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-022-09895-5
Allahyari, Abolghasem; Ehsanpour, Ali; Najafi, Behrouz; Ansarinejad, Nafiseh; Mehrzad, Valiollah; Kalantari, Behjat; Raafat, Jahangir; Ghadiany, Mojtaba; Shahi, Farhad; Gharib, Behrooz; Moazed, Vahid; Khosravi, Adnan; Mirpour, Mir Hossein; Salari, Sina; Mortazavizadeh, Seyedmohammadreza; Nekoyi, Amirabbas; Khani, Mohsen; Sadeghi, Alireza; Gharib, Sirus; Bary, Alireza; Mirzania, Mehrzad; Haghighat, Shirin; Razavi, Seyed Mohsen; Emami, Seyed Amir Hossein; Hosseinzadeh, Mehran; Mirbolouk, Mahdi; Sadighi, Sanambar; Shahrasbi, Abdolali; Esfahani, Ali; Gity, Masoumeh; Anjidani, Nassim; Kafi, Hamidreza; Najafi, Safa
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2022
文献求助 收藏

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

更正：一项随机、III期等效性临床试验，比较拟上市的帕妥珠单抗生物类似药P013与参考产品在HER2阳性乳腺癌患者中的疗效和安全性。

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-022-10455-0
Allahyari, Abolghasem; Ehsanpour, Ali; Najafi, Behrouz; Ansarinejad, Nafseh; Mehrzad, Valiollah; Kalantari, Behjat; Raafat, Jahangir; Ghadiany, Mojtaba; Shahi, Farhad; Gharib, Behrooz; Moazed, Vahid; Khosravi, Adnan; Mirpour, Mir Hossein; Salari, Sina; Mortazavizadeh, Seyedmohammadreza; Nekoyi, Amirabbas; Khani, Mohsen; Sadeghi, Alireza; Gharib, Sirus; Bary, Alireza; Mirzania, Mehrzad; Haghighat, Shirin; Razavi, Seyed Mohsen; Emami, Seyed Amir Hossein; Hosseinzadeh, Mehran; Mirbolouk, Mahdi; Sadighi, Sanambar; Shahrasbi, Abdolali; Esfahani, Ali; Gity, Masoumeh; Anjidani, Nassim; Kaf, Hamidreza; Najaf, Safa
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2022
文献求助 收藏

Post-Marketing Surveillance of a generic Oxaliplatin (Alvoxal(Ⓡ)) in Iranian Patients with Cancer

伊朗癌症患者中仿制奥沙利铂（Alvoxal®）的上市后监测

期刊:Current Therapeutic Research-Clinical and Experimental
影响因子:1.5
doi:10.1016/j.curtheres.2021.100657
Shahi, Farhad; Gorji, Mojtaba; Payandeh, Mehrdad; Rezvani, Hamid; Vaezi, Mohammad; Seifi, Sharareh; Baari, Alireza; Khalili-Dizaji, Reza; Hashemi, Seyed Mehdi; Salimi, Saeid; Kamranzadeh, Hosein; Shazad, Babak; Salari, Sina; Dameshghi, Davoud Oulad; Sarkheil, Mehdi; Mirzania, Mehrzad; Anjidani, Nassim
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis

托珠单抗治疗重症和危重症 COVID-19 的疗效和安全性：系统评价和荟萃分析

期刊:Expert Review of Clinical Immunology
影响因子:3.7
doi:10.1080/1744666X.2021.1908128
Rezaei, Soheila; Fatemi, Behzad; Karimi Majd, Zahra; Minaei, Hossein; Peikanpour, Mohammad; Anjidani, Nassim; Taheri, Ali; Dastan, Farzaneh; Mosaed, Reza
发表日期：2021
文献求助 收藏